AstraZeneca shares: is the company a bargain after the vaccine candidate news?

Jay Yao discusses whether he thinks AstraZeneca is a bargain given the recent release of the company’s Covid-19 vaccine candidate data

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One of the most anticipated events in the history of AstraZeneca (LSE:AZN) occurred this week. The company, in conjunction with Oxford University, released an interim analysis of their Covid-19 vaccine candidate, AZD1222.

AZN’s vaccine candidate showed an average 70% efficacy and there were no safety concerns. Excitingly, one of the company’s dosing regimens could be up to 90% effective.  

Although the vaccine candidate showed a lot of potential, AstraZeneca shares nevertheless fell slightly given that both Pfizer and Moderna’s vaccine candidates had around 95% efficacy. 

Given the decline in shares, is the stock a bargain?

Long-term potential of AstraZeneca shares 

With a forward P/E ratio of around 21, AstraZeneca shares aren’t exactly cheap.

Given technology advancements, however, I think the company is a bargain at current prices for the long term. 

Technology has the potential to affect pharmaceutical companies substantially. With the continual development of quantum computing and AI, there could be huge breakthroughs in pharma and biotech in the coming decades. 

As one of the leaders in the sector, AZN is in a great position to benefit, in my view. With its R&D prowess and resources, I think it could be one of the key companies that develops blockbuster drugs in the future. 

If AZN develops worthy solutions to address big global problems, I feel the company’s profits could grow substantially. 

Emerging and developing markets

As for AZD1222, AZN’s vaccine could help its future profit growth in one its target sectors, emerging and developing markets. 

As I have written before, AZN has an extensive operation in the emerging and developing world. The company is also committed to growing its operations in those regions.

In terms of growing business in emerging and developing markets, I think AZN’s vaccine could be a great door-opener, if approved. 

Although they might be more efficacious on the surface, Pfizer and Moderna’s vaccines require substantially cooler temperatures than AZN’s and are more expensive. That’s a big plus for AstraZeneca. 

AstraZeneca isn’t trying to make money from the vaccine in low-to-middle-income countries while the pandemic still rages, and I feel this could also help its appeal in emerging markets.

Once emerging and developing nations become richer, I see the pharmaceuticals giant as potentially profiting from having established a strong base already. 

With possibly less need for heavy marketing spend, it could mean higher future margins and higher profits in the long run if things go AZN’s way. 

Is AstraZeneca a bargain?

Although AZN’s stock price has decreased since the company released its interim analysis of AZD1222, I think the decline is an opportunity for long-term investors.

AZN has many competitive strengths given its scale, financial resources, and R&D capabilities. I like the company’s pipeline and I think it could grow its earnings faster if emerging and developing markets grow faster than expected. 

Looking at the share’s valuation and the fact that I’m bullish on the future of emerging and developing markets, I really do think AstraZeneca is a bargain today. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jay Yao has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »